Movement Alert｜HBM HOLDINGS-B Rises 5.02% in Regular Trading, Core Pipeline HBM9378 Posts Positive Phase II Interim Data in Asthma and Initiates Phase III

Market Focus

Yesterday

On September 9, HBM HOLDINGS-B rose 5.02% in regular trading, trading at HKD 15.27 per share, with turnover of approximately HKD 63.46 million.

The rally was driven by partner Windward Bio AG announcing on September 8 that HBM9378/WIN378 achieved positive Phase II interim results in the global Phase II/III POLARIS-1 clinical study for asthma, with Phase III now formally initiated. HBM9378/WIN378 is a fully human ultra-long-acting monoclonal antibody targeting TSLP with a unique dual-epitope binding mechanism. Pharmacokinetic data show a half-life of up to 75 days, supporting a twice-yearly dosing regimen. The Phase III portion is evaluating two dosing regimens versus placebo, with annualized asthma exacerbation rate as the primary endpoint. Safety data showed no treatment-related serious adverse events, with injection-site reactions below 1%.

Additionally, the company's shares were officially included in the Hang Seng Composite Index and became eligible for Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect trading from September 7, which is expected to broaden the investor base and enhance liquidity.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/news/1115757914"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115757914\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115757914?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115757914","market":"hk","top_or_hot":-1,"title":"Movement Alert｜HBM HOLDINGS-B Rises 5.02% in Regular Trading, Core Pipeline HBM9378 Posts Positive Phase II Interim Data in Asthma and Initiates Phase III","media":"Market Focus","content":"<p><p>On September 9, HBM HOLDINGS-B rose 5.02% in regular trading, trading at HKD 15.27 per share, with turnover of approximately HKD 63.46 million.</p><p>The rally was driven by partner Windward Bio AG announcing on September 8 that HBM9378/WIN378 achieved positive Phase II interim results in the global Phase II/III POLARIS-1 clinical study for asthma, with Phase III now formally initiated. HBM9378/WIN378 is a fully human ultra-long-acting monoclonal antibody targeting TSLP with a unique dual-epitope binding mechanism. Pharmacokinetic data show a half-life of up to 75 days, supporting a twice-yearly dosing regimen. The Phase III portion is evaluating two dosing regimens versus placebo, with annualized asthma exacerbation rate as the primary endpoint. Safety data showed no treatment-related serious adverse events, with injection-site reactions below 1%.</p><p>Additionally, the company's shares were officially included in the Hang Seng Composite Index and became eligible for Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect trading from September 7, which is expected to broaden the investor base and enhance liquidity.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HBM HOLDINGS-B Rises 5.02% in Regular Trading, Core Pipeline HBM9378 Posts Positive Phase II Interim Data in Asthma and Initiates Phase III</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HBM HOLDINGS-B Rises 5.02% in Regular Trading, Core Pipeline HBM9378 Posts Positive Phase II Interim Data in Asthma and Initiates Phase III\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-09 10:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 9, HBM HOLDINGS-B rose 5.02% in regular trading, trading at HKD 15.27 per share, with turnover of approximately HKD 63.46 million.</p><p>The rally was driven by partner Windward Bio AG announcing on September 8 that HBM9378/WIN378 achieved positive Phase II interim results in the global Phase II/III POLARIS-1 clinical study for asthma, with Phase III now formally initiated. HBM9378/WIN378 is a fully human ultra-long-acting monoclonal antibody targeting TSLP with a unique dual-epitope binding mechanism. Pharmacokinetic data show a half-life of up to 75 days, supporting a twice-yearly dosing regimen. The Phase III portion is evaluating two dosing regimens versus placebo, with annualized asthma exacerbation rate as the primary endpoint. Safety data showed no treatment-related serious adverse events, with injection-site reactions below 1%.</p><p>Additionally, the company's shares were officially included in the Hang Seng Composite Index and became eligible for Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect trading from September 7, which is expected to broaden the investor base and enhance liquidity.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1115757914","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115757914","pubTimestamp":1788921554,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 9, HBM HOLDINGS-B rose 5.02% in regular trading, trading at HKD 15.27 per share, with turnover of approximately HKD 63.46 million.The rally was driven by partner Windward Bio AG...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"走势警报|HBM HOLDINGS-B 常规交易上涨 5.02%，核心管道 HBM9378 在哮喘方面发布积极的 II 期中期数据并启动 III 期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"On September 9, HBM HOLDINGS-B rose 5.02% in regular trading, trading at HKD 15.27 per share, with turnover of approximately HKD 63.46 million.The rally was driven by partner Windward Bio AG announcing on September 8 that HBM9378/WIN378 achieved positive Phase II interim results in the global Phase II/III POLARIS-1 clinical study for asthma, with Phase III now formally initiated. HBM9378/WIN378 is a fully human ultra-long-acting monoclonal antibody targeting TSLP with a unique dual-epitope binding mechanism. Pharmacokinetic data show a half-life of up to 75 days, supporting a twice-yearly dosing regimen. The Phase III portion is evaluating two dosing regimens versus placebo, with annualized asthma exacerbation rate as the primary endpoint. Safety data showed no treatment-related serious adverse events, with injection-site reactions below 1%.Additionally, the company's shares were officially included in the Hang Seng Composite Index and became eligible for Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect trading from September 7, which is expected to broaden the investor base and enhance liquidity.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}